Literature DB >> 1159080

Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol.

B S Chertow, D J Baylink, J E Wergedal, M H Su, A W Norman.   

Abstract

The present study determined the effects of 1,25-dihydroxycholecalciferol on serum immunoactive parathyroid hormone and on parathyroid hormone secretion in vitro. Rats injected i.p. with 1,25-dihydroxycholecalciferol, 130 pmol (2 U)/140 g body wt, which is probably a physiologic dose, had a significant 43% decrease in serum immunoreactive parathyroid hormone at 4 h. In addition, this dose of 1,25-dihydroxycholecalciferol inhibited the serum immunoreactive parathyroid hormone response to hypocalcemia induced by phosphate injection. Because the increment in serum immunoreactive parathyroid hormone was less but the decrement in serum calcium more in phosphate plus 1,25-dihydroxycholecalciferol-treated than in phosphate plus vehicle-treated rats, the impaired serum immunoreactive parathyroid hormone response to 1,25-dihydroxycholecalciferol could not be attributed to the change in serum calcium. In studies of parathyroid hormone secretion from bovine parathyroid tissue in vitro, the concentration of 1,25-dihydroxycholecalciferol used for most experiments was 1nM, which is in the range found in rat serum. 1,25-Dihydroxycholecalciferol at 1 or 100 nM significantly inhibited parathyroid hormone secretion when medium calcium concentration was normal (1.5 mM), high (3.0 mM), and low (1.0 mM). Maximum inhibition ranged from 19 to 74%; inhibition was generally seen after 2 h of incubation; and inhibition was sustained or progressive thereafter. Vitamin A, 0.1 muM, caused a marked stimulation of parathyroid hormone secretion. 1,25-Dihydroxycholecalciferol at 1 nM markedly reduced (44%) the effect of vitamin A to stimulate parathyroid hormone secretion. This effect of 1,25-dihydroxycholecalciferol was maximal at 1 h and persisted thereafter. Another steroid, hydrocortisone, 10 muM, did not inhibit parathyroid hormone secretion, suggesting that the 1,25-dihydroxycholecalciferol effect was not a nonspecific inhibitory effect on parathyroid cells. Because other workers have shown that parathyroid hormone directly stimulates 1,25-dihydroxycholecalciferol secretion, our results are consistent with the concept that there is a feedback loop where parathyroid hormone directly stimulates secretion of 1,25-dihydroxycholecalciferol, which in turn directly inhibits secretion of parathyroid hormone.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1159080      PMCID: PMC301915          DOI: 10.1172/JCI108137

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  The interactions between vitamin A, vinblastine, and cytochalasin B in parathyroid hormone secretion.

Authors:  B S Chertow; G A Williams; R Kiani; K L Stewart; G K Hargis; R L Flayter
Journal:  Proc Soc Exp Biol Med       Date:  1974-10

2.  Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism.

Authors:  G A Lumb; S W Stanbury
Journal:  Am J Med       Date:  1974-06       Impact factor: 4.965

3.  Studies on the biosynthesis of rat parathyroid hormone and proparathyroid hormone: adaptation of the parathyroid gland to dietary restriction of calcium.

Authors:  L L Chu; R R MacGregor; C S Anast; J W Hamilton; D V Cohn
Journal:  Endocrinology       Date:  1973-10       Impact factor: 4.736

4.  Nature of human parathyroid hormone secreted by monolayer cell cultures.

Authors:  T J Martin; P B Greenberg; R A Melick
Journal:  J Clin Endocrinol Metab       Date:  1972-02       Impact factor: 5.958

5.  Subcellular mechanisms of parathyroid hormone secretion: ultrastructural changes in response to calcium, vitamin A, vinblastine, and cytochalasin B.

Authors:  B S Chertow; R J Buschmann; W J Henderson
Journal:  Lab Invest       Date:  1975-02       Impact factor: 5.662

6.  Heterogeneity of parathyroid hormone. Clinical and physiologic implications.

Authors:  R Silverman; R S Yalow
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

7.  Evidence for a precursor to circulating parathyroid hormone.

Authors:  L M Sherwood; J S Rodman; W B Lundberg
Journal:  Proc Natl Acad Sci U S A       Date:  1970-11       Impact factor: 11.205

8.  Parathyroid hormone: secretion and metabolism in vivo.

Authors:  J F Habener; D Powell; T M Murray; G P Mayer; J T Potts
Journal:  Proc Natl Acad Sci U S A       Date:  1971-12       Impact factor: 11.205

9.  The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma.

Authors:  J E Smith; D S Goodman
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

10.  Embryonic chick intestine in organ culture. A unique system for the study of the intestinal calcium absorptive mechanism.

Authors:  R A Corradino
Journal:  J Cell Biol       Date:  1973-07       Impact factor: 10.539

View more
  37 in total

1.  Dissociation of renal cyclic AMP and phosphate responses to parathyroid hormone in uremia.

Authors:  J E Russell; M Kleerekoper; E Slatopolsky; J Lewis; S W Lee; L V Avioli
Journal:  Calcif Tissue Int       Date:  1979-11-26       Impact factor: 4.333

Review 2.  The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).

Authors:  Luisella Cianferotti; Claudio Cricelli; John A Kanis; Ranuccio Nuti; Jean-Y Reginster; Johann D Ringe; Rene Rizzoli; Maria Luisa Brandi
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

3.  Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.

Authors:  J A Kanis; R G Henderson; G Heynen; J G Ledingham; R G Russell; R Smith; R J Walton
Journal:  Arch Dis Child       Date:  1977-06       Impact factor: 3.791

4.  Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog.

Authors:  W E Rutherford; P Bordier; P Marie; K Hruska; H Harter; A Greenwalt; J Blondin; J Haddad; N Bricker; E Slatopolsky
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

5.  1,25-Dihydroxyvitamin D3: mode of action in intestine and parathyroid glands, assay in humans and isolation of its glycoside from Solanum malacoxylon.

Authors:  M R Haussler; M R Hughes; T A McCain; J E Zerwekh; P F Brumbaugh; W Jubiz; R H Wasserman
Journal:  Calcif Tissue Res       Date:  1977-05

6.  Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.

Authors:  J A Delmez; C Tindira; P Grooms; A Dusso; D W Windus; E Slatopolsky
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

7.  Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.

Authors:  S Lopez-Hilker; T Galceran; Y L Chan; N Rapp; K J Martin; E Slatopolsky
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

8.  Reversal of secondary hyperparathyroidism by cimetidine in chronically uremic dogs.

Authors:  A I Jacob; J M Canterbury; G Gavellas; P W Lambert; J J Bourgoignie
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

9.  Inhibition by 1,25 dihydroxycholecalciferol of hormonal secretion of rat parathyroid gland in organ culture.

Authors:  W Y Au
Journal:  Calcif Tissue Int       Date:  1984-07       Impact factor: 4.333

10.  Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog.

Authors:  J M Canterbury; S Lerman; A J Claflin; H Henry; A Norman; E Reiss
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.